ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to ad...
ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).
Founded Year
1984
Organization Website
imclone.com
Organization Languages
English
Organization Revenue
300000
Current Technologies
csc corporate domains
office 365
Job Functions
Engineering
Education
Information Technology
Business Development
Operations
Consulting
Marketing
Finance
Media And Commmunication
Support
Administrative
Human Resources
Legal
Sales
monoclonal antibodies
biopharmaceutical company
biotechnology
therapeutics
genetics
Ling Gao's Work History and Education
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
Associate Director, Global Clinical Pharmacology
2011 - Present
Colleagues at
Imclone Systems A Whollyowned Subsidiary Of Eli Lilly And Company